If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Visual toxicities were observed with use of abemaciclib in the MONARCH clinical trials.
of Visual Toxicities
most common abemaciclib visual toxicities in MONARCH 2, and MONARCH 3
are presented in Table 1.
1. All Grade Visual Toxicities in the Abemaciclib Arms of the MONARCH
the abemaciclib plus fulvestrant arm of MONARCH 2, photopsia was
experienced in 2 patients (0.5%) and scintillating scotoma was
experienced in 1 patient (0.2%).1
3 unilateral blindness was experienced by 1 patient (0.3%) in the
abemaciclib plus nonsteroidal aromatase inhibitor arm of MONARCH 3.
Aside from the patient who experienced unilateral blindness in
MONARCH 3, all other visual toxicities experienced by patients in
MONARCH 2, and MONARCH 3 were of grade 1 or grade 2 severity.1
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:August 19, 2020
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org